Efficacy of dupilumab against pruritus in dystrophic epidermolysis bullosa: Real-life data from a retrospective bicentric study.
作者信息
Chiaverini Christine, Kandemir Stéphane, Hubiche Thomas, Bourrat Emmanuelle, Hovnanian Alain
机构信息
Department of Dermatology, MAGEC-Sud Hôpital Archet 2, Université Nice Côte d'Azur, Nice, France.
Department of Dermatology, MAGEC-Nord Hôpital Saint Louis, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France.
出版信息
J Eur Acad Dermatol Venereol. 2025 Apr;39(4):e353-e355. doi: 10.1111/jdv.20327. Epub 2024 Sep 13.
PMID:39269013
Abstract
摘要
相似文献
1
Efficacy of dupilumab against pruritus in dystrophic epidermolysis bullosa: Real-life data from a retrospective bicentric study.度普利尤单抗治疗营养不良性大疱性表皮松解症瘙痒的疗效：一项回顾性双中心研究的真实世界数据
J Eur Acad Dermatol Venereol. 2025 Apr;39(4):e353-e355. doi: 10.1111/jdv.20327. Epub 2024 Sep 13.
2
Pruritus Anesis in Dystrophic Epidermolysis Bullosa Pruriginosa with Dupilumab.杜普利尤单抗治疗痒感消退型营养不良性大疱性表皮松解症所致瘙痒
Adv Skin Wound Care. 2024 Feb 1;37(2):1-4. doi: 10.1097/ASW.0000000000000096.
3
Epidermolysis bullosa pruriginosa treated with dupilumab.用度普利尤单抗治疗的瘙痒性大疱性表皮松解症。
Pediatr Dermatol. 2021 Mar;38(2):526-527. doi: 10.1111/pde.14493. Epub 2020 Dec 18.
4
Efficacy and Safety of Dupilumab Monotherapy in Patients With Dystrophic Epidermolysis Bullosa: A Retrospective Study of 8 Cases.度普利尤单抗单药治疗营养不良型大疱性表皮松解症患者的疗效和安全性：8例回顾性研究
J Dermatol. 2025 Jul;52(7):1159-1165. doi: 10.1111/1346-8138.17753. Epub 2025 Apr 24.
5
Dominant dystrophic epidermolysis bullosa is associated with glycolytically active GATA3+ T helper 2 cells which may contribute to pruritus in lesional skin.显性营养不良型大疱性表皮松解症与糖酵解活性的 GATA3+T 辅助 2 细胞相关，这些细胞可能导致皮损皮肤的瘙痒。
Br J Dermatol. 2024 Jul 16;191(2):252-260. doi: 10.1093/bjd/ljae110.
6
Successful treatment of epidermolysis bullosa pruriginosa by dupilumab.成功使用度普利尤单抗治疗瘙痒性大疱性表皮松解症。
J Dermatol. 2023 Jun;50(6):837-842. doi: 10.1111/1346-8138.16729. Epub 2023 Jan 24.
7
Real-world experience of using dupilumab and JAK inhibitors to manage pruritus in epidermolysis bullosa pruriginosa.使用度普利尤单抗和JAK抑制剂治疗痒疹型大疱性表皮松解症瘙痒的真实世界经验。
Skin Health Dis. 2024 Aug 19;4(5):e445. doi: 10.1002/ski2.445. eCollection 2024 Oct.
8
Efficacy of oral JAK1 or JAK1/2 inhibitor for treating refractory pruritus in dystrophic epidermolysis bullosa: A retrospective case series.口服 JAK1 或 JAK1/2 抑制剂治疗营养不良性大疱性表皮松解症难治性瘙痒的疗效：回顾性病例系列。
J Dermatol. 2024 Mar;51(3):441-447. doi: 10.1111/1346-8138.17079. Epub 2023 Dec 20.
9
A case of junctional epidermolysis bullosa intermediate with collagen XVII deficiency treated with dupilumab.十七型胶原缺陷性交界型大疱性表皮松解症一例应用度普利尤单抗治疗。
J Dermatolog Treat. 2023 Dec;34(1):2253943. doi: 10.1080/09546634.2023.2253943. Epub 2023 Nov 15.
10
Sporadic dystrophic epidermolysis bullosa with concomitant atopic dermatitis.散发性营养不良性大疱性表皮松解症伴发特应性皮炎。
Br J Dermatol. 1998 Feb;138(2):315-20. doi: 10.1046/j.1365-2133.1998.02082.x.
引用本文的文献
1
Prevalence and Mechanisms of Itch in Chronic Wounds: A Narrative Review.慢性伤口瘙痒的患病率及机制：一项叙述性综述
J Clin Med. 2025 Apr 22;14(9):2877. doi: 10.3390/jcm14092877.
2
The Role of Fibroblasts in Dystrophic Epidermolysis Bullosa Pathogenesis and Current Treatment Approaches.成纤维细胞在营养不良性大疱性表皮松解症发病机制中的作用及当前治疗方法
JID Innov. 2025 Feb 4;5(3):100353. doi: 10.1016/j.xjidi.2025.100353. eCollection 2025 May.
Zotero 插件